These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32222450)

  • 21. Letter from the Editor: Cost-effectiveness of tuberculosis screening in patients already on biologic therapy.
    Elston DM
    J Am Acad Dermatol; 2022 Oct; 87(4):747-748. PubMed ID: 35643245
    [No Abstract]   [Full Text] [Related]  

  • 22. Practice guideline for treatment of latent tuberculosis infection in children.
    Nicholson EG; Geltemeyer AM; Smith KC
    J Pediatr Health Care; 2015; 29(3):302-7. PubMed ID: 25792195
    [No Abstract]   [Full Text] [Related]  

  • 23. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
    Faivre C; Villani AP; Aubin F; Lipsker D; Bottaro M; Cohen JD; Durupt F; Jeudy G; Sbidian E; Toussirot E; Badot V; Barbarot S; Debarbieux S; Delaporte E; Goegebeur G; Morel J; Nassif A; Duru G; Jullien D;
    J Am Acad Dermatol; 2016 Jun; 74(6):1153-9. PubMed ID: 26965410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of hidradenitis suppurativa with biologic medications.
    Lee RA; Eisen DB
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered.
    Egeberg A; Thyssen JP
    Lancet; 2023 Mar; 401(10378):708-710. PubMed ID: 36746172
    [No Abstract]   [Full Text] [Related]  

  • 26. Latent tuberculosis infection: diagnostic update before introduction of biological drugs.
    Martinez-Lopez A; Ruiz-Villaverde R
    Eur J Dermatol; 2016 Jun; 26(3):307-8. PubMed ID: 26985763
    [No Abstract]   [Full Text] [Related]  

  • 27. Screening for Latent Tuberculosis Infection: A Key Step Toward Achieving Tuberculosis Elimination in the United States.
    Reves R; Daley CL
    JAMA Intern Med; 2016 Oct; 176(10):1439-1440. PubMed ID: 27599130
    [No Abstract]   [Full Text] [Related]  

  • 28. Prevalence of positive QuantiFERON gold in-tube testing in hidradenitis suppurativa.
    Boortalary T; Misra K; McNish S; Jones D; Shanmugam VK
    J Dermatolog Treat; 2018 Sep; 29(6):637-640. PubMed ID: 29325465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Latent tuberculosis infection screening prior to biological treatment in Tunisian patients.
    Slouma M; Mahmoud I; Saidane O; Bouden S; Abdelmoula L
    Therapie; 2017 Oct; 72(5):573-578. PubMed ID: 28318613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: a combined approach by QuantiFERON-TB Gold and tuberculin skin tests.
    Prignano F; Bartoloni A; Bartalesi F; Gori A; Ricceri F; Cavallo A; Attala L; Mantella A
    Int J Dermatol; 2014 Aug; 53(8):e372-4. PubMed ID: 24898978
    [No Abstract]   [Full Text] [Related]  

  • 31. Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts.
    Sánchez-Moya AI; Daudén E
    Br J Dermatol; 2011 Jan; 164(1):208-9. PubMed ID: 21054332
    [No Abstract]   [Full Text] [Related]  

  • 32. Ustekinumab, another biologic with potential to help patients with hidradenitis suppurativa?
    Eisen DB
    Br J Dermatol; 2016 Apr; 174(4):718-9. PubMed ID: 27115586
    [No Abstract]   [Full Text] [Related]  

  • 33. Don't Be Late on Latent TB: Inconsistent Tuberculosis Screening in IBD Patients on Biologics.
    Szvarca D; Borum ML
    J Crohns Colitis; 2019 Feb; 13(2):270. PubMed ID: 30247658
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Focus on latent tuberculosis.
    The Lancet Respiratory Medicine
    Lancet Respir Med; 2016 Oct; 4(10):763. PubMed ID: 27707455
    [No Abstract]   [Full Text] [Related]  

  • 36. Screening and Treatment of Latent Tuberculosis Among Patients Receiving Biologic Agents: A National and International Survey of Rheumatologists.
    Tran NQ; Garcia-Rosell M; Pattanaik D; Raza SH; Carbone L
    J Clin Rheumatol; 2017 Jan; 23(1):6-11. PubMed ID: 28002150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deployment-related testing and treatment for latent tuberculosis infection, part II.
    Mancuso JD; Keep LW
    Mil Med; 2011 Oct; 176(10):1088-92. PubMed ID: 22128639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with psoriasis are more likely to be treated for latent tuberculosis infection prior to biologics than patients with inflammatory bowel disease.
    Bassukas ID; Kosmidou M; Gaitanis G; Tsiouri G; Tsianos E
    Acta Derm Venereol; 2011 Jun; 91(4):444-6. PubMed ID: 21547342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detect to Prevent: Evaluating Testing and Treatment Practices for Latent Tuberculosis Infection in Long-Term Care Facilities.
    Winston CA; Stone ND
    J Am Geriatr Soc; 2017 Jun; 65(6):1139-1140. PubMed ID: 28306136
    [No Abstract]   [Full Text] [Related]  

  • 40. Intention of physicians to implement guidelines for screening and treatment of latent tuberculosis infection in HIV-infected patients in The Netherlands: a mixed-method design.
    Evenblij K; Verbon A; van Leth F
    BMC Public Health; 2016 Sep; 16(1):915. PubMed ID: 27585867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.